Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4442-4451

  Soria, Jean Charles ^a   Márk, Zsuzsanna ^c   Zatloukal, Petr ^e   Szima, Barna ^c   Albert, István ^c   Juhász, Erzsébet ^d   Pujol, Jean Louis ^b   Kozielski, Jerzy ^f   Baker, Nigel ^g   Smethurst, Dominic ^g   Hei, Yong Jiang ⁱ   Ashkenazi, Avi ^j   Stern, Howard ^j   Amler, Lukas ^j   Pan, Yang ⁱ   Blackhall, Fiona ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c Tüdogyógyintézet Törökbálint ^*  (Hungary)

^d Orszagos Koranyi Tbc es Pulmonologiai Intezet   (Hungary)

^e UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^f Katedra I Klinika Chorób P uc I Gru licy Slaskiego Uniwersytetu Medycznego   (Poland)

^g AMGEN LTD   (United Kingdom)

^h CHRISTIE HOSPITAL   (United Kingdom)

ⁱ AMGEN INC   (United States)

^j GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYTOKERATIN 18; DULANERMIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KERATIN-18; LUNG NEOPLASMS; MALE; MIDDLE AGED; N-ACETYLGALACTOSAMINYLTRANSFERASES; PACLITAXEL; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 81755161607     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.2623     Document Type: Article

References (42)

1. Sandler A, Gray R, Perry MC, et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
2. Johnson DH, Fehrenbacher L, Novotny WF, et al.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004 (Pubitemid 41095154)
3. Camidge DR: The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancer. Clin Lung Cancer 8:413-419, 2007
4. Igney FH, Krammer PH: Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer 2:277-288, 2002 (Pubitemid 37328781)
5. Rowinsky EK: Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 23:9394-9407, 2005
6. Ashkenazi A, Herbst RS: To kill a tumor cell: The potential of proapoptotic receptor agonists. J Clin Invest 118:1979-1990, 2008 (Pubitemid 351872316)
7. Ashkenazi A, Holland P, Eckhardt SG: Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26:3621-3630, 2008
8. Spierings DC, de Vries EG, Timens W, et al.: Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9:3397-3405, 2003 (Pubitemid 37082735)
9. Mizobe T, Ogata Y, Murakami H, et al.: Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma. Oncol Rep 20:517-523, 2008
10. Wedam SB, Low JA, Yang SX, et al.: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24:769-777, 2006 (Pubitemid 46622044)
11. Yildiz R, Benekli M, Buyukberber S, et al.: The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer. J Cancer Res Clin Oncol 136:1471-1476, 2010
12. Hylander BL, Pitoniak R, Penetrante RB, et al.: The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3:22, 2005
13. Pollack IF, Erff M, Ashkenazi A: Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 7:1362-1369, 2001 (Pubitemid 32708693)
14. Jin H, Yang R, Fong S, et al.: Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 64:4900-4905, 2004 (Pubitemid 38924535)
15. Naka T, Sugamura K, Hylander BL, et al.: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62:5800-5806, 2002 (Pubitemid 35204738)
16. Ashkenazi A, Pai RC, Fong S, et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162, 1999
17. Wagner KW, Punnoose EA, Januario T, et al.: Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13:1070-1077, 2007 (Pubitemid 47517508)
18. Stern HM, Padilla M, Wagner K, et al.: Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clin Cancer Res 16:1587-1596, 2010
19. Herbst RS, Eckhardt SG, Kurzrock R, et al.: Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28:2839-2846, 2010
20. Soria JC, Smit E, Khayat D, et al.: Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28:1527-1533, 2010
21. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
22. Camidge DR, Herbst RS, Gordon MS, et al.: A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 16:1256-1263, 2010
23. Karapetis CS, Clingan PR, Leighl NB, et al.: Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC). J Clin Oncol 28:546s, 2010 (suppl; abstr 7535)
24. Von Pawel J, Harvey JH, Spigel DR, et al.: A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC. J Clin Oncol 28:539s, 2010 (suppl; abstr LBA7501)
25. Goss GD, Arnold A, Shepherd FA, et al.: Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28:49-55, 2010
26. Goss G, Shepherd FA, Laurie S, et al.: A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 45:782-788, 2009
27. Leong S, Cohen RB, Gustafson DL, et al.: Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase I and pharmacokinetic study. J Clin Oncol 27:4413-4421, 2009
28. Reference deleted
29. Langer CJ, Besse B, Gualberto A, et al.: The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28:5311-5320, 2010
30. Reck M, von Pawel J, Zatloukal P, et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27:1227-1234, 2009
31. Schiller JH, Harrington D, Belani CP, et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
32. Blumenschein GR Jr, Kabbinavar F, Menon H, et al.: A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 22:2057-2067, 2011
33. Frese S, Brunner T, Gugger M, et al.: Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 123:168-174, 2002
34. Odoux C, Albers A, Amoscato AA, et al.: TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer 97:458-465, 2002 (Pubitemid 34027804)
35. Kramer G, Erdal H, Mertens HJ, et al.: Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64:1751-1756, 2004 (Pubitemid 38428698)
36. Leers MP, Kolgen W, Bjorklund V, et al.: Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187:567-572, 1999 (Pubitemid 29151999)
37. Dive C, Smith RA, Garner E, et al.: Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer 102:577-582, 2010
38. De Petris L, Branden E, Herrmann R, et al.: Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. Eur J Cancer 47:131-137, 2011
39. Brandt D, Volkmann X, Anstatt M, et al.: Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas. Eur J Cancer 46:1464-1473, 2010
40. de Haas EC, di Pietro A, Simpson KL, et al.: Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 10:1041-1048, 2008
41. Khambata-Ford S, Harbison CT, Hart LL, et al.: Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 28:918-927, 2010
42. Douillard JY, Shepherd FA, Hirsh V, et al.: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. J Clin Oncol 28:744-752, 2010